CombiGene carries out a directed new issue of shares to Lipigon Pharmaceuticals

Oct 24, 2019

The board of directors of CombiGene AB (publ) (”CombiGene”) has, on the basis of an authorisation from the Annual General Meeting, resolved on a directed issue of 1,322,751 new shares to Lipigon Pharmaceuticals AB (”Lipigon”) due to the license agreement that CombiGene has entered into with Lipigon, which has reinforced CombiGene’s position as Sweden’s leading gene therapy company.

The share issue is conducted in order to settle the upfront payment to Lipigon in accordance with the license agreement and results in a dilution of approximately 2 percent of the share capital of CombiGene after the new issue of shares. The upfront payment amounts to SEK 1,499,999.63 and the number of shares has been determined on the basis of a subscription price that corresponds to the volume-weighted average price of CombiGene’s share during a period of fifteen (15) trading days ending the day before the board’s decision on the issue of shares. The new shares will be transferred to Lipigon as soon as the issue has been registered with the Swedish Companies Registration Office.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook